AI Engines For more Details: Perplexity Kagi Labs You
Protein Synthesis: L-Lysine is crucial for protein synthesis, aiding in the formation of new proteins. It is particularly important for the synthesis of collagen, the main structural protein in connective tissues, skin, bones, and cartilage.
Antiviral Activity: L-Lysine has been studied for its potential antiviral properties, particularly in managing herpes simplex virus (HSV) infections, including cold sores (oral herpes) and genital herpes. Some research suggests that L-lysine supplementation may help reduce the frequency, severity, and duration of herpes outbreaks by inhibiting the replication of the virus.
Bone Health: L-Lysine plays a role in calcium absorption and collagen formation, both of which are essential for bone health. Adequate lysine intake may contribute to bone strength and density, potentially reducing the risk of osteoporosis and bone fractures.
Wound Healing: L-Lysine is involved in tissue repair and wound healing processes. It promotes the production of collagen, which is necessary for the formation of scar tissue and the closure of wounds. Some studies suggest that L-lysine supplementation may accelerate wound healing and improve tissue regeneration.
Immune Function: L-Lysine is important for maintaining a healthy immune system. It supports the production of antibodies, which are essential for immune defense against pathogens such as bacteria and viruses. Lysine deficiency may impair immune function and increase susceptibility to infections.
Carnitine Synthesis: L-Lysine is a precursor for the synthesis of carnitine, a compound involved in fatty acid metabolism and energy production. Carnitine plays a critical role in transporting fatty acids into mitochondria, where they are converted into energy. Adequate lysine levels are necessary for optimal carnitine production and energy metabolism.
Collagen Formation: L-Lysine is a key amino acid in collagen synthesis, contributing to the stability and integrity of collagen fibers. Collagen is essential for maintaining the structure and elasticity of skin, blood vessels, tendons, and other connective tissues.
Anxiety and Stress Management: Some studies suggest that L-Lysine may have anxiolytic (anti-anxiety) effects and could help modulate stress responses. It is thought to exert its effects by influencing neurotransmitter pathways in the brain, including serotonin and GABAergic neurotransmission.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
Allergies | 0.5 | 0.5 | 0 |
Allergy to milk products | 0.4 | 0.7 | -0.75 |
Alzheimer's disease | 0.8 | 0.8 | |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.5 | 1 |
Ankylosing spondylitis | 1 | 0.8 | 0.25 |
Anorexia Nervosa | 0.5 | 0.5 | |
Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
Asthma | 0.5 | 0.5 | 0 |
Atrial fibrillation | 0.9 | 0.7 | 0.29 |
Autism | 1.2 | 1.2 | 0 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.5 | 0.5 | |
Brain Trauma | 0.7 | 0.7 | |
Carcinoma | 0.4 | 0.4 | |
Celiac Disease | 0.5 | 0.5 | 0 |
Chronic Fatigue Syndrome | 0.4 | 0.4 | |
Chronic Kidney Disease | 0.3 | 0.3 | |
Chronic Lyme | 0.5 | 0.5 | |
Chronic Urticaria (Hives) | 0.2 | 0.2 | |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.7 | |
Colorectal Cancer | 1.2 | 1.2 | |
Constipation | 1 | 1 | |
COVID-19 | 1 | 1 | |
Crohn's Disease | 1.4 | 0.4 | 2.5 |
cystic fibrosis | 0.3 | 0.3 | |
deep vein thrombosis | 0.7 | 0.7 | |
Depression | 1 | 0.5 | 1 |
Eczema | 0.8 | 0.8 | |
Endometriosis | 0.8 | 0.8 | |
Epilepsy | 0.5 | 0.5 | |
Functional constipation / chronic idiopathic constipation | 1 | 1 | |
gallstone disease (gsd) | 0.3 | 0.3 | |
Generalized anxiety disorder | 0.3 | 0.3 | |
Graves' disease | 0.5 | -0.5 | |
Hashimoto's thyroiditis | 0.2 | -0.2 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | |
hyperglycemia | 0.3 | 0.3 | |
hypersomnia | 0.2 | 0.2 | |
hypertension (High Blood Pressure | 0.5 | 0.2 | 1.5 |
IgA nephropathy (IgAN) | 0.5 | 0.5 | |
Inflammatory Bowel Disease | 0.7 | 0.2 | 2.5 |
Irritable Bowel Syndrome | 1.2 | 0.4 | 2 |
Liver Cirrhosis | 1.2 | 1.2 | |
Long COVID | 1.5 | 0.9 | 0.67 |
Lung Cancer | 0.3 | 0.3 | |
Metabolic Syndrome | 1 | 1 | |
Mood Disorders | 1 | 1 | 0 |
myasthenia gravis | 0.5 | -0.5 | |
Neuropathy (all types) | 0.2 | -0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 1 | |
Obesity | 1.2 | 1.2 | |
obsessive-compulsive disorder | 1 | 1 | |
Osteoarthritis | 0.2 | 0.2 | |
Osteoporosis | 0.3 | 0.3 | |
Parkinson's Disease | 0.7 | 0.5 | 0.4 |
Polycystic ovary syndrome | 0.8 | 0.8 | |
Postural orthostatic tachycardia syndrome | 0.5 | 0.5 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 0.2 | 6 |
Rosacea | 0.2 | -0.2 | |
Schizophrenia | 0.2 | 0.5 | -1.5 |
Sjögren syndrome | 0.3 | 0.3 | |
Sleep Apnea | 0.7 | 0.7 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
Stress / posttraumatic stress disorder | 0.7 | 0.7 | |
Systemic Lupus Erythematosus | 1 | 1 | |
Type 1 Diabetes | 0.2 | 0.2 | |
Type 2 Diabetes | 1 | 1 | |
Ulcerative colitis | 1.2 | 0.3 | 3 |
Unhealthy Ageing | 0.5 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.